Skip to main content

Curaleaf shares tumble 8% after FDA warning letter over CBD health claims

Shares of cannabis company Curaleaf Holdings Inc. slid 7% Tuesday, after the U.S. Food and Drug Administration issued a warning letter to the company for selling CBD-based products that it claims can treat serious diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.